MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Kamada Ltd Company Profile (NASDAQ:KMDA)

Consensus Ratings for Kamada Ltd (NASDAQ:KMDA) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.50 (134.81% upside)

Analysts' Ratings History for Kamada Ltd (NASDAQ:KMDA)
Show:
DateFirmActionRatingPrice TargetActions
2/11/2016HC WainwrightReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/13/2015Jefferies GroupLower Price TargetBuy$8.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/7/2015RBC CapitalSet Price TargetBuy$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/8/2014OppenheimerInitiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Kamada Ltd (NASDAQ:KMDA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
2/2/2016Q415($0.09)$0.03$27.10 million$25.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.04)($0.13)$18.67 million$16.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q215($0.03)($0.06)$21.82 million$19.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.05)($0.15)$16.12 million$9.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/11/2015Q4$0.01$0.05ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014Q314($0.04)($0.09)$19.00 million$17.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($0.02)($0.23)$17.17 million$15.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.03)($0.09)$15.97 million$13.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/5/2014Q413$0.05$0.04$25.22 million$24.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Kamada Ltd (NASDAQ:KMDA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.11)($0.11)($0.11)
Q2 20161($0.04)($0.04)($0.04)
Q3 20161($0.01)($0.01)($0.01)
Q4 20161$0.01$0.01$0.01
(Data provided by Zacks Investment Research)
Dividend History for Kamada Ltd (NASDAQ:KMDA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Kamada Ltd (NASDAQ:KMDA)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Kamada Ltd (NASDAQ:KMDA)
DateHeadline
06/23/16 06:00 AMKamada Announces Appointment of Naveh Tov, M.D., Ph.D., to Vice President, Clinical Development and Medical Director for Pulmonary Diseases - [GlobeNewswire] - NESS ZIONA, Israel, June 23, 2016-- Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, today announced the appointment of Naveh Tov, M.D., Ph.D., to the position ...
06/15/16 04:52 PMFDA approves self-infusion of Glassia
05/12/16 11:49 AMKamada Ltd. :KMDA-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/09/16 05:56 AMKamada Reports 2016 First Quarter Financial Results - [at noodls] - May. 9, 2016 NESS ZIONA, Israel (May 9, 2016) - Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces financial results for the three ...
05/09/16 05:34 AMKamada reports 1Q loss -
05/05/16 08:09 AMNew Kamada CEO optimistic despite European setback - Pharmaceutical company Kamada Ltd. (TASE: KMDA) received two milestone payments on Monday from Chiesi and Baxalta - undisclosed sums, which are believed to be a few million dollars. The Chiesi installment was paid following the submission of a marketing ...
05/04/16 07:30 AMKamada to Host First Quarter Financial Results Conference Call on May 9, 2016 at 8:30 am Eastern Time - [Business Wire] - Kamada Ltd. , a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the first quarter ended March 31, 2016 prior to the open of the U.S.
05/02/16 06:00 AMKamada Receives Two Milestone Payments under Strategic Agreements with Chiesi Farmaceutici and Baxalta - [Business Wire] - Kamada Ltd. , a plasma-derived protein therapeutics company focused on orphan indications, announces receipt of two milestone payments as a result of achieving certain regulatory and sales milestones under the strategic agreements with Chiesi Farmaceutici S.p.A.
04/07/16 12:40 PMKamada (KMDA) Commences AAT Phase 2 for Lung Transplant Rejection Prevention - Kamada Ltd. (Nasdaq: KMDA) announces in the initiation of a Phase 2 clinical trial with its proprietary Alpha-1 Antitrypsin (AAT) for the prevention of lung transplant rejection. The study is being conducted in collaboration with Baxalta Incorporated (NYSE ...
04/07/16 06:02 AMKamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection - [at noodls] - Apr. 7, 2016 NESS ZIONA, Israel (April 6, 2016) - Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces in the initiation of a Phase ...
03/30/16 01:32 PMKamada Submits Marketing Authorization Application with the European … - Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the submission of a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA (News - Alert)) for the ...
03/28/16 05:30 AM6:30 am Kamada submits a Marketing Authorization Application with the EMA for its inhaled alpha-1 antitrypsin therapy as a treatment for AAT deficiency -
03/28/16 05:30 AMKamada Submits Marketing Authorization Application with the European Medicines Agency for its Proprietary Inhaled Alpha-1 Antitrypsin to Treat Alpha-1 Antitrypsin Deficiency - [Business Wire] - Kamada Ltd. , a plasma-derived protein therapeutics company focused on orphan indications, announces the submission of a Marketing Authorization Application with the European Medicines Agency for the Company’s proprietary, inhaled alpha-1 antitrypsin therapy as a treatment for AAT deficiency . The filing was validated by the EMA.
02/05/16 11:35 AMKamada Ltd. Earnings Analysis: 2015 By the Numbers -
02/05/16 07:56 AMKamada to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference - [Business Wire] - Kamada Ltd. , a plasma-derived protein therapeutics company focused on orphan indications, announced today that the Company will participate at the Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference taking place February 10-11, 2016 in New York City.
02/04/16 08:30 AMNew Strong Buy Stocks for February 4th -
02/02/16 06:37 AMKamada posts 4Q profit -
02/02/16 06:17 AMKamada Reports 2015 Fourth Quarter and Full Year Financial Results - [Business Wire] - Kamada Ltd. , a plasma-derived protein therapeutics company focused on orphan indications, reports financial results for the three and 12 months ended December 31, 2015.
01/27/16 09:54 AM30 am Eastern time - Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the three and twelve months ended December 31, 2015 prior to the open of the U.S. stock ...
01/27/16 09:41 AMKamada to Host Fourth Quarter and Year End 2015 Financial Results Conference Call on February 2, 2016 at 8:30 am Eastern time - [Business Wire] - Kamada Ltd. , a plasma-derived protein therapeutics company focused on orphan indications, announces that it will release financial results for the three and twelve months ended December 31, 2015 prior to the open of the U.S.
01/06/16 06:52 AMKamada Reports Further Positive Interim Data from Phase 1/2 Study of its Alpha-1 Antitrypsin to Treat Graft Versus Host Disease - [at noodls] - Jan. 6, 2016 NESS ZIONA, Israel (January 6, 2016) - Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, reports further positive interim results ...
12/29/15 03:40 PMKamada (KMDA) Reports Encouraging Data on Rabies Drug -
12/23/15 12:12 PMKamada Ltd. Earnings Analysis: Q3, 2015 By the Numbers -
12/23/15 08:30 AMNew Strong Sell Stocks for December 23rd -
12/23/15 07:17 AMKamada’s Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment - [at noodls] - Kamada's Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment Dec. 23, 2015 NESS ZIONA, Israel (December 23, 2015) - Kamada ...
12/23/15 05:17 AMKamada's rabies drug succeeds in trial -
12/09/15 05:17 AMKamada Completes Enrollment of U.S. Phase 2 Study of Inhaled Alpha-1 Antitrypsin for the Treatment of AAT Deficiency - [at noodls] - Dec. 8, 2015 NESS ZIONA, Israel (December 8, 2015) - Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the completion of enrollment ...
12/09/15 05:17 AMKamada Provides Update on Alpha-1 Antitrypsin Development in Newly Diagnosed Type 1 Diabetes - [at noodls] - Dec. 2, 2015 NESS ZIONA, Israel (December 2, 2015) - Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces it will un-blind the current ...
12/08/15 12:09 PMKAMADA LTD Financials -
12/01/15 07:30 AMKamada to Present at the Oppenheimer 26th Annual Healthcare Conference - [Business Wire] - Kamada Ltd. , a plasma-derived protein therapeutics company focused on orphan indications, announces that Company management will participate at the Oppenheimer 26th Annual Healthcare Conference being held from December 8-9, 2015 at the Westin Grand Central Hotel in New York City.
About Kamada Ltd

Kamada Ltd logoKamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company's product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy. Its product line also comprises Protosol to reduce blood loss in patients undergoing cardiac surgery; Heparin sodium injection for coagulation inhibition and prophylaxis of thromboembolic diseases and Heparin Lock Flush to maintain potency of intravenous injection device among other.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: KMDA
  • CUSIP:
Key Metrics:
  • Previous Close: $3.62
  • 50 Day Moving Average: $3.77
  • 200 Day Moving Average: $3.89
  • P/E Ratio: N/A
  • P/E Growth: -5.58
  • Market Cap: $138.70M
  • Current Quarter EPS Consensus Estimate: $-0.11 EPS
Additional Links:
Kamada Ltd (NASDAQ:KMDA) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha